B cells and tertiary lymphoid structures promote immunotherapy response
2020 · Nature · 2,551 citations
https://doi.org/10.1038/s41586-019-1922-8
R
Rafet Başar
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
175
Papers
8.4K
Citations
30
h-index
47
i10-index
Rafet Başar is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Immune Cell Function and Interaction & CAR-T cell therapy research & Cancer Immunotherapy and Biomarkers. The author has an h-index of 30, co-authored 149 publications.
ORCID: 0000-0003-4713-0454Papers by this author
worksUse of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
2020 · New England Journal of Medicine · 2,002 citations
https://doi.org/10.1056/nejmoa1910607
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
2024 · Nature Medicine · 403 citations
https://doi.org/10.1038/s41591-023-02785-8
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape
2022 · Nature Medicine · 152 citations
https://doi.org/10.1038/s41591-022-02003-x
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
2021 · Clinical Cancer Research · 147 citations
https://doi.org/10.1158/1078-0432.ccr-21-0164
Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy
2021 · Cell Reports · 33 citations
https://doi.org/10.1016/j.celrep.2021.109432
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat